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Abstract 
Purpose: To evaluate the effect of Lycium barbarum polysaccharide (LBP) on apoptosis in 
Mycoplasma-infected splenic lymphocytes (SLs), and the underlying mechanisms.  
Methods: SLs isolated from C57BL/6J mice were infected with Mycoplasma. The infected SLs were 
administered at different concentrations of LBP for 4 h, and the proportions of apoptotic cells and levels 
of relative reactive oxygen species (ROS) were determined by flow cytometry. The expressions of pro-
apoptotic genes and endogenous antioxidant enzymes were investigated by real-time polymerase chain 
reaction (RT-PCR) and Western blotting. 
Results: LBP treatment produced dose-dependent reductions in apoptotic ratio and intracellular ROS 
levels of SLs (p < 0.05). In addition, the expressions of pro-apoptotic genes were decreased by LBP 
treatment with respect to mRNA and protein levels (p < 0.05). In contrast, mRNA and protein levels of 
anti-apoptotic factor Bcl-2 were significantly increased in a dose-dependent manner (p < 0.05). 
Furthermore, RT-PCR and Western blot results demonstrated that the expression levels of mRNA and 
proteins in Nrf2, HO-1 and NQO1 were up-regulated by Mycoplasma infection (p < 0.01), and further 
increased by LBP treatment (p < 0.05). 
Conclusion: LBP exerts a hyperactive antioxidant response encoded by Nrf2 to protect SLs from 
apoptosis induced by ROS-related oxidative damage after Mycoplasma infection. These results suggest 
that LBP may serve as a beneficial and dietary anti-Mycoplasma and anti-apoptotic agent. 
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Mycoplasma has significant impacts on many 
human diseases [1]. Immune responses are 
believed to play roles in protection from 
Mycoplasma diseases [1]. In Chinese traditional 
medicine, the use of Lycium barbarum as a 
functional food for promoting immunity and 
longevity were documented as far back as 2,800 
BC [2]. Studies have shown that Lycium 
barbarum polysaccharide (LBP), a major active 
component of Lycium barbarum, attenuates 
cytotoxicity, lowers blood glucose, enhances 
immunity, and also possesses anti-cancer 
properties [3-5]. Apoptosis is closely associated 
with lymphocyte development and homeostasis 
[6]. Enhanced or inhibited apoptosis in 
lymphocyte can lead to immunodeficiency or 
autoimmunity, or lymphoma [6]. LBP plays an 
important role in lymphocyte proliferation and 
cytokine production [7,8]. A recent study reported 
that LBP has beneficial effects on 
spermatogenesis through regulation of apoptosis 
and antioxidant activity in diabetic male mice [9]. 
However, little is known about the effect of LBP 
on apoptosis in lymphocytes.  
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Reactive oxygen species (ROS) have been 
considered as messengers of phagocytes 
involved in defense against pathogen invasion 
[10]. They are involved in lymphocytes activation, 
hypo- responsiveness, and apoptosis [10]. 
Recent studies indicate that LBP has antioxidant 
properties [9,11]. Thus, this study was aimed at 
investigating the effects of LBP on apoptotic 
signaling induced by ROS-related oxidative 
damage in splenic lymphocytes (SLs) after 






Mycoplasma (MP) species (ATCC 15488, Ziker 
Biotech, China) was cultured in modified Friis 
broth containing 2.5 % CO2, at 37 °C. The culture 
medium was centrifuged at 18,000 g for 20 min 
at 4 °C, to harvest the Mycoplasma. The cells 
were washed thrice in PBS (pH 7.4), and 
suspended in RPMI 1640 medium. It was 
previously reported that at 540 nm, an 
absorbance of 0.2 was equivalent to 108 colony-
forming units per ml (CFU/mL) of Mycoplasma 
[12]. Thus, the concentration of Mycoplasma was 




Water extraction and ethanol precipitation were 
employed to extract LBP from Lycium barbarum 
fruit. Dried fruits of Lycium barbarum were 
ground to fine powder and extracted in water at 4 
°C overnight. The Lycium barbarum residue was 
then extracted three times in boiling water. Then, 
the aqueous extract was concentrated and 
precipitated using 5 volumes of 100% ethanol. 
The precipitate was dried to obtain the crude 
LBP, which was then purified using DEAE-
cellulose ion exchange chromatography. Prior to 
administration, the LBP was dissolved in PBS 
and filtered through a 0.22 μm filter. 
 
Cell culture and grouping 
 
Splenic lymphocyte cell line (obtained from 
ATCC, USA) was cultured in RPMI-16 40 
medium supplemented with 10 % fetal bovine 
serum (FBS) at 37 °C in a 5 % CO2-humidified 
incubator. The cells were divided into 7 groups: 
control group, and six Mycoplasma (20 cfu/mL) 
groups, containing different LBP concentrations 
as follows: 0 (vehicle), 20, 50, 100, 200, and 400 
μg/mL (coded MP, LBP 20, LBP 50, LBP 100, 
LBP 200 and LBP 400, respectively). Cellular 
apoptosis was determined 4 h after treatment. 
 
Flow cytometry analysis 
 
SLs were harvested and washed twice with PBS. 
Then, the cell pellet was re-suspended in 
washing buffer. For the apoptosis analysis, the 
cells were stained with PI dye at 4 °C for 30 min, 
followed by examination using a FACSCanto II 
cytometer (BD Biosciences, Germany). The 
percentage of apoptotic cells was calculated. 
 
In order to determine the level of ROS, SLs were 
incubated with fluorescent probe DCFH-DA (10 
uM) at 37 °C for 30 min. Then, after washing, 
intracellular ROS were quantified by FACSCanto 
II cytometer (BD Biosciences, Germany). 
 
Quantitative real-time PCR 
 
SLs were washed with PBS and RNA was 
extracted using RNeasy Plus Micro Kit (QIAGEN, 
USA), followed by cDNA synthesis using 
SuperScript® IV First-Strand Synthesis System 
(Invitrogen, USA). PCR primers (with sequences) 
of the target genes were as follows: β-Actin 
(internal control): 5′- TGC TGT GTT CCC ATC 
TAT CG -3′ (forward) and 5′- TTG GTG ACA 
ATA CCG TGT TCA -3′ (reverse); Caspase-3: 5′- 
TGG CCC TCT TGA ACT GAA AG -3′ (forward) 
and 5′- TCC ACT GTC TGC TTC AAT ACC -3′ 
(reverse); BAX: 5′- TCC TCA TCG CCA TGC 
TCA T -3′ (forward) and 5′- CCT TGG TCT GGA 
AGC AGA AGA -3′ (reverse); Bcl-2: 5′- GAT GAC 
CGA GTA CCT GAA CC -3′ (forward) and 5′- 
CAG GAG AAA TCG AAC AAA GGC -3′ 
(reverse); Nrf2: 5′- GAC GGTA TGC AAC AGG 
ACA TTG AG -3′ (forward) and 5′- AAC TTC TGT 
CAG TTT GGC TTC TGG A -3′ (reverse); NQO1: 
5′- GGA TTG GAC CGA GCT GGA A -3′ 
(forward) and 5′- AAT TGC AGT GAA GAT GAA 
GGC AAC -3′ (reverse); HO-1: 5′- ACA TCG 
ACA GCC CCA CCA AGT TCAA -3′ (forward) 
and 5′- CTG ACG AAG TGA CGC CAT CTG 
TGAG -3′ (reverse). The RT-PCR was conducted 
in a 25-ߤL reaction volume (7500 Fast Real-time 
PCR System, ABI, USA) using 20 ng template, 
Power SYBR® Green PCR Master Mix 
(Invitrogen, USA), and gene-specific primer pairs 
for pro-apoptotic genes (Caspase-3 and Bax), 
anti-apoptosis factor Bcl-2, and antioxidant 
enzyme genes (Nrf2, HO-1, and NQO1). 
Amplification conditions were as follows: 95 °C, 2 
min; 30 cycles of 95 °C, 30 s, 65 °C, 30 s, 72 °C, 
1 min; 72 °C, 5 min. The relative quantification of 
target genes was calculated by ΔΔCT method. 
 
Western blot analysis 
 
Cells were lysed in an ice-cold hypotonic lysis 
buffer (containing proteinase inhibitor cocktail 
and PMSF) and centrifuged at 10,000 rpm at 4 
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°C for 3 min. The protein concentration was 
measured using BCA Protein Assay reagent kit 
(Thermo Fisher Scientific, USA). The cell lysates 
-g of protein) were subjected to 10 % SDSߤ 20)
PAGE. Then, the gel was electro-transferred 
onto a PVDF membrane. After blocking with 5 % 
skimmed milk, the membrane was successively 
incubated with anti Caspase-3, Bax, Bcl-2, Nrf2, 
HO-1, and NQO1 primary antibodies (1:1000; 
Abcam, USA) and goat anti-rabbit IgG-HRP 
secondary antibody (1:2000; Abcam, USA). 
Bands were detected by ECL kit (Thermo Fisher 
Scientific, USA). Target gene expression levels 





All data are presented as mean ± standard 
deviation (SD). For multiple group comparisons, 
one-way analysis of variance (ANOVA) and 
appropriate post-hoc analysis were performed 
using a statistical software package (Prism5, 





LBP prevented SLs apoptosis 
 
The LBP-treated groups exhibited dose-
dependent reductions in the apoptotic ratio of 
SLs when compared to the MP-infected group 
(Figure 1). When the LBP concentration reached 
100 μg/mL, the apoptotic ratio of SLs was 
significantly decreased relative to the MP- 
infected group (p < 0.05). The apoptotic ratio in 
the 400 μg/mL LBP treated group was decreased 
to a level similar to the control group. These data 
indicate that LBP is an effective anti-apoptotic 
agent in SLs. 
 
 
Figure 1: Effect of LBP treatment on apoptosis in SLs. (A) Apoptosis of Mycoplasma-infected SLs (b) and SLs 
treated with vehicle (a), 20 (c), 50 (d), 100 (e), 200 (f), and 400 (g) μg/mL LBP at 4 h was evaluated using PI 
staining and flow cytometry analysis. (B) Quantitative analysis of the apoptotic cells under different treatment 
conditions; **p < 0.01, versus MP group; #p < 0.05, versus control group; ##p < 0.01, versus the control group; 
Results are presented as mean ± SD of three experiments. MP = Mycoplasma; LBP = Lycium barbarum 
polysaccharide 
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LBP prevented accumulation of intracellular 
ROS 
 
Flow cytometry analysis showed a dose-
dependent decrease in intracellular levels of 
ROS in SLs. When the LBP concentration 
reached 400 μg/mL, ROS levels were 
significantly decreased when compared to the 
MP group (p < 0.05, Figure 2). These results 
indicate that ROS clearance may be a 
mechanism involved in the protective effect of 
LBP on the apoptosis of mycoplasma-infected 
SLs. 
 
LBP regulated the expressions of pro-
apoptotic genes 
 
The expressions of pro-apoptotic genes, 
caspase-3 and Bax, were decreased by LBP 
treatment at both mRNA and protein levels. In 
the 200 and 400 μg/mL groups, the relative 
expressions of these genes decreased 
significantly when compared with the MP group 
(p < 0.01, Figure 3). In contrast, both mRNA and 
protein levels of the anti-apoptotic factor Bcl-2 
were significantly increased in a dose-dependent 
manner when compared with the 200 and 400 
μg/mL MP groups (p < 0.01). 
 
 
Figure 2: Effect of LBP treatment on ROS production. (A) ROS levels of Mycoplasma infected SLs (b) and SLs 
treated with 0 (vehicle) (a), 20 (c), 50 (d), 100 (e), 200 (f), and 400 (g) μg/mL LBP at 4 h were evaluated using 
DCFH-DA fluorescence by flow cytometry. (B) The geometric mean of fluorescence ± SD; **p < 0.01, versus the 
MP group; #p < 0.05, versus the control group; MP = mycoplasma; LBP = Lycium barbarum polysaccharide 
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Figure 3: Effect of LBP on the expression of pro-apoptotic genes. (A) Relative mRNA expression of caspase3, 
Bax, and Bcl-2 were determined by RT-PCR. (B) Bands of caspase3, Bax, and Bcl-2 determined by Western 
blotting. (C) Quantitative analysis of Western blot result; *p < 0.05, versus the MP group; **p < 0.01, versus the 
MP group; #p < 0.05, versus the control group; MP = Mycoplasma; LBP = Lycium barbarum polysaccharide 
 
LBP up-regulated antioxidant enzymes 
through Nrf2 signaling pathway 
 
Results of qPCR and Western blot show that the 
mRNA and protein levels of Nrf2 were 
significantly up-regulated by Mycoplasma 
infection (p < 0.01 when compared with the 
control group. Figure 4). LBP treatment for 4 h 
further increased the Nrf2 expressions, when 
compared with the MP group (for mRNA levels: p 
< 0.01 in the 50 to 400 μg/mL groups; for protein 
levels: p < 0.01 in the 400 μg/mL group), HO-1 
(for mRNA levels: p < 0.01 in the 200 to 400 
μg/mL groups; for protein levels: p < 0.01 in the 
50 to 400 μg/mL groups), and NQO1 (for mRNA 
levels: p < 0.01 in the 50 to 400 μg/mL groups; 
for protein levels: p < 0.01 in the 200 to 400 
μg/mL groups; Figure 4). These results support 





In this study, Mycoplasma-infected SLs were 
used to investigate the role of LBP in antioxidant 
defense against immunologic injury. It was found 
that Mycoplasma infection increased apoptosis 
and ROS accumulation in SLs. However, LBP 
treatment reduced the ROS levels, increased the 
activation of Nrf2 pathway, and inhibited 
apoptotic signals. A growing body of evidence 
indicate that LBP and Lycium barbarum have a 
variety of immuno-modulatory functions. Some 
researchers reported that LBP can induce 
phenotypic and functional maturation of dendritic 
cells via NF κB signaling pathways [13,14]. It 
has been shown that LBP can act as an adjuvant 
for the generation of Tfh cells to enhance T cell-
dependent antibody responses [15]. It has also 
been demonstrated that LBP can promote 
cytokine secretion in macrophages, Th1, and 
Th2 [16]. Researchers have consistently shown 
that LBP significantly induces proliferation of T 
lymphocytes [4,17]. However, not much was 
hitherto know about the anti-apoptotic and 
antioxidant effects of LBP in lymphocytes. To the 
best of our knowledge, the present study is the 
first to demonstrate the anti-apoptotic property of 
LBP in SLs through the Nrf2 pathway, thereby 
providing a deeper understanding of its beneficial 
properties in immunocytes. 
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Figure 4: Effect of LBP on expression of antioxidant enzyme genes. (A) Relative mRNA expression of Nrf2, HO-
1, and NQO1 were determined by RT-PCR. (B) Bands of Nrf2, HO-1, and NQO1 determined by Western blotting. 
(C) Quantitative analysis of Western blot results; *p < 0.05, versus MP group; **p < 0.01, versus MP group; # p < 
0.05, versus control group; MP = Mycoplasma; LBP = Lycium barbarum polysaccharide 
 
Numerous studies have reported that the Nrf2 
signaling pathway plays a critical role in cellular 
defense against oxidative stress. Some 
researchers used Keap1-deficient mice and 
found that T-cell–specific augmentation of Nrf2 
increased antioxidant response and reduced 
intracellular cytokine production by T-cells [18]. 
Nrf2-KO mice developed inflammatory lesions 
and autoimmune syndromes, and decreases in 
expressions of HO-1 and NQO1 [19]. HO-1 and 
NQO1 are two well-recognized downstream 
factors of the Nrf2 signaling pathway. HO-1 is as 
a potent radical scavenger known to protect cells 
against oxidative stress [20]. Studies with HO-1-
knockout mice which exhibit increased 
susceptibility to oxidative insults proved that HO-
1 is involved in the endogenous defense against 
oxidative stress [20]. NQO1 is a flavoprotein 
which prevents the participation of quinones in 
redox cycling, thereby sequestering ROS [21]. 
However, there is lack of data on the role of Nrf2 
signaling pathway in SLs infected with 
Mycoplasma. Thus, the effect of Mycoplasma on 
activation of Nrf2 and its downstream antioxidant 
enzymes (HO-1 and NQO1) was investigated in 
the present study. The results obtained suggest 
that the Nrf2 pathway is involved in the survival 
of Mycoplasma-infected SLs, and that LBP 
treatment protects the infected SLs through the 
clearance of ROS.  
CONCLUSION 
 
The results of this study indicate that LBP can 
protect Mycoplasma-infected SLs from ROS-
induced apoptosis through a mechanism 
involving a hyperactive antioxidant response 
encoded by Nrf2. This finding provides evidence 
to show that LBP may serve as a beneficial and 
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